About Chugai

We dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world.

Everything we do is based on this mission.

We work for the wellbeing of each and every patient, who all have different lifestyles, values, treatment needs, and priorities, and for the advancement of medical care around the world.

We believe that pursuing innovation with new ideas leads to sharing value with all stakeholders.

Chugai’s Strengths

Chugai’s Strengths

Strengthened by unique science and technology
R&D-oriented pharmaceutical company

Chugai is working to satisfy unmet medical needs by developing innovative new drugs using its unique technology and science, including antibody engineering technology.

Chugai has gained a reputation worldwide for its high level of drug discovery capabilities, backed by a diverse research infrastructure, including the advancement of unique antibody engineering technologies.

Unique Technology and Science

Creation of the first therapeutic antibody originating in Japan. World-leading technological capabilities in antibodies and mid-size molecules

  • Share of therapeutic antibody sales in Japan*1

    No.1

  • Breakthrough Therapeutics Designations*2 *2

    9times

  • Innovative new drugs
    as a percentage of sales*3

    67%

  • Countries approving Chugai products

    More than
    110

  • *1 Copyright © 2025 IQVIA. Calculated based on JPM 2024. Reprinted with permission. The scope of the market is defined by Chugai.
  • *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.
  • *3 Proportion of sales from products that qualify for premium pricing. (2024)

One of Japan’s top prescription pharmaceutical manufacturers

  • Sales Revenue

    1trillion
    1,706
    billion yen

    • (Consolidated, fiscal year ending December 2024)

  • Operating profit

    5,561
    billion yen

    • (Consolidated, fiscal year ending December 2024)

  • Number of Employees

    7,778

    • (Consolidated, as of December 31, 2024)

Business Strategy

Based on the strategic alliance with Roche, we aim to "achieve advanced, sustainable patient-centric healthcare"

Chugai's basic management policy is "Creating Shared Value," and we aim to solve social issues and achieve sustainable development. We will create shared value by "realizing advanced, sustainable patient-centric healthcare" through innovation that only we can produce by making the most of our science and technology and our unique business model based on our strategic alliance with Roche.

Chugai's Value Creation Model

Chugai has adopted “creating shared value” as its basic management policy, in line with the philosophy of growing together with its various stakeholders by resolving social issues through business activities. The following value creation model explains the cycle in which both our company and society achieve sustainable development.

Strategic Alliance with Roche

By building a stable revenue base through sales of Roche products in Japan, Chugai is now able to focus on more challenging, innovative research and development and original projects. We have also achieved greater research efficiency by sharing a drug discovery platform with Roche.

Growth Strategy "TOP I 2030”

The Chugai Group has formulated the growth strategy "TOP I 2030" in order to achieve our vision. We are working on a new stage of transformation based on the strategic alliance with Roche, aiming to achieve further competitive advantage as well as sustainable profit growth and an expansion of corporate value.

History of Chugai Pharmaceutical

History of Chugai Pharmaceutical

A company that continues to innovate while carrying on the spirit of its founding

Our founding spirit in 1925 was to "make drugs that benefit society."

Even after 100 years have passed, our founding commitment to "for patients" remains unchanged.

History of Chugai Pharmaceutical

People and Activities

Toward the creation of continuous innovation.
The Story of Our Challenges.

  • #Digital Technology
  • #Open Innovation
  • #Co-Creation

CHUGAI INNOVATION DAY 2024 Report—More Than 3,000 in Attendance

Chugai Pharmaceutical’s CHUGAI INNOVATION DAY 2024 was hosted on November 25 (Mon) and 26 (Tue), 2024. This was the fifth hosting of the CHUGAI INNOVATIO

  • Innovation
  • R&D
  • DX
  • Event
  • #Digital Technology
  • #Co-Creation

Takao Suzuki was previously an employee at Microsoft where he supported numerous companies as director of the DX strategy advisory department. He now works as Head of the DX Unit at Chugai Pharmaceutical. According to Suzuki, what are the key factors to ensuring the successful implementation of DX?

Aiming to become the top innovator in the healthcare industry, Chugai Pharmaceutical has positioned DX as a fundamental element of its growth strategy. Phase 1

  • Innovation
  • DX
  • CHUGAI DIGITAL VISION 2030
  • Top Interview
  • #Science and Technology
  • #Digital Technology
  • #Sustainability

Greater Efficiency in Bioprocess Development. Digital Transformations in Pharmaceuticals

Chugai Pharmaceutical is currently promoting companywide DX to achieve the targets of its new growth strategy Top I 2030. The company is focusing on innovative

  • Innovation
  • R&D
  • DX
  • Sustainability
  • CHUGAI DIGITAL VISION 2030
  • Production Technology
  • #Science and Technology

Working to Reform the Drug Discovery Process—Acceleration of Drug Discovery Research Using Cryo-EM

Torizawa is general manager of the Protein Science Research Department. He is currently in charge of the early stages of drug discovery to uncover molecules th

  • Innovation
  • R&D
  • Recruitment
  • Research
  • Cryo-Electron Microscopy
  • #Science and Technology
  • #Digital Technology

Working Toward Greater Efficiency in the Drug Discovery Process for Mid-size Molecules. Development of a Crystallization Confirmation App Using Agile Development Methods

Agile development has recently been garnering attention as a method that involves quickly ascertaining needs and progressing with a project in an agile and fle

  • Innovation
  • R&D
  • DX
  • Mid-Molecule Pharmaceuticals
  • #Science and Technology

From the medical frontlines to a pharmaceutical company. Medical doctors leveraging their clinical experience to contribute to the creation of pharmaceuticals

Chugai Pharmaceutical, with its R&D bases and global development functions in Japan, has strived to conduct clinical studies based on medical grounds and o

  • Innovation
  • R&D
  • Recruitment
  • Human Resources
  • Medical Doctor
  • #Science and Technology
  • #Digital Technology

Maximizing Drug Discovery Through Team Capabilities. Delivering Innovative Drugs to Patients with Process and Technological Development

Kondo is an employee at the pharmaceutical research department. Within his group, in addition to overseeing process development and manufacturing technology tr

  • Innovation
  • R&D
  • DX
  • Recruitment
  • Mid-Molecule Pharmaceuticals
  • Production Technology
  • #Science and Technology

The future of drug discovery opened up by a research environment with a high degree of freedom. Using diverse modalities to create innovative pharmaceuticals

Chugai Pharmaceutical’s strengths lie in its world-leading antibody drug discovery technologies and advanced small-molecule drug discovery research. The

  • Innovation
  • R&D
  • Recruitment
  • Research
  • Drug Discovery Modalities
  • Production Technology

Contents List

Understanding Chugai: Our Company and History

Message from the CEO

Our Vision

Our Strategy

Company Outline

Supplier

View in Japanese